HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine].

Abstract
A 26-year-old man was referred to our hospital with vomiting and high fever. He was disoriented and laboratory results showed microangiopathic hemolytic anemia (Hb 7.1 g/dl) and severe thrombocytopenia (15 x 10(3)/microl). The diagnosis of thrombotic thrombocytopenic purpura (TTP) was established. The activity of von Willebrand cleaving protease (ADAMTS13) was found to be remarkably low (<0.5%) and the high activity of the inhibitor (11.0 Bethesda U/ml) was detected, confirming the diagnosis of typical acquired TIP. Although he had been successfully treated with daily plasma exchange and methylprednisolone, he relapsed after a week. To this therapeutic strategy we added four weekly doses of rituximab (375 mg/m2) and two weekly doses of vincristine (1 mg/m2) simultaneously. The response was very rapid and complete, that is, the platelet count recovered to normal seven days after the first rituximab and vincristine treatment. The patient maintains complete remission nine months later under the administration of 17.5 mg prednisolone. Recovery of the plasma ADAMTS13 activity was clearly correlated with the decrease or disappearance of the inhibitor activity. Combination of rituximab and vincristine therapy would appear to be very effective against refractory TTP.
AuthorsHitomi Kaneko, Masanori Matsumoto, Kohei Okamoto, Kazuhisa Chyonabayashi, Masakatsu Hishizawa, Mitsumasa Watanabe, Yoshihiro Fujimura, Mitsuru Tsudo
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 48 Issue 2 Pg. 144-7 (Feb 2007) ISSN: 0485-1439 [Print] Japan
PMID17370643 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents, Phytogenic
  • Biomarkers
  • Rituximab
  • Vincristine
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
Topics
  • ADAM Proteins (blood)
  • ADAMTS13 Protein
  • Adult
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents, Phytogenic
  • Biomarkers (blood)
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Humans
  • Male
  • Plasma Exchange
  • Purpura, Thrombotic Thrombocytopenic (diagnosis, therapy)
  • Rituximab
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: